A detailed history of Tower Research Capital LLC (Trc) transactions in Terns Pharmaceuticals, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 6,117 shares of TERN stock, worth $35,478. This represents 0.0% of its overall portfolio holdings.

Number of Shares
6,117
Previous 8,725 29.89%
Holding current value
$35,478
Previous $59,000 13.56%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$6.49 - $10.8 $16,925 - $28,166
-2,608 Reduced 29.89%
6,117 $51,000
Q2 2024

Aug 13, 2024

BUY
$4.54 - $8.2 $36,801 - $66,469
8,106 Added 1309.53%
8,725 $59,000
Q1 2024

May 15, 2024

SELL
$4.86 - $8.19 $108,752 - $183,267
-22,377 Reduced 97.31%
619 $4,000
Q4 2023

Feb 13, 2024

BUY
$3.37 - $6.86 $73,944 - $150,522
21,942 Added 2081.78%
22,996 $149,000
Q3 2023

Nov 14, 2023

SELL
$4.7 - $8.55 $32,697 - $59,482
-6,957 Reduced 86.84%
1,054 $5,000
Q2 2023

Aug 14, 2023

BUY
$7.35 - $13.29 $32,053 - $57,957
4,361 Added 119.48%
8,011 $70,000
Q1 2023

May 09, 2023

SELL
$7.91 - $12.0 $14,941 - $22,668
-1,889 Reduced 34.1%
3,650 $43,000
Q4 2022

Feb 10, 2023

SELL
$4.62 - $10.18 $4,906 - $10,811
-1,062 Reduced 16.09%
5,539 $57,000
Q3 2022

Nov 10, 2022

SELL
$1.87 - $6.42 $7,253 - $24,903
-3,879 Reduced 37.01%
6,601 $39,000
Q2 2022

Aug 15, 2022

BUY
$1.5 - $3.0 $10,386 - $20,772
6,924 Added 194.71%
10,480 $26,000
Q1 2022

May 12, 2022

BUY
$2.83 - $6.7 $5,696 - $13,487
2,013 Added 130.46%
3,556 $11,000
Q4 2021

Feb 14, 2022

BUY
$5.65 - $10.73 $4,429 - $8,412
784 Added 103.29%
1,543 $11,000
Q3 2021

Nov 15, 2021

SELL
$7.22 - $13.46 $3,039 - $5,666
-421 Reduced 35.68%
759 $8,000
Q2 2021

Aug 16, 2021

BUY
$12.26 - $22.0 $6,939 - $12,452
566 Added 92.18%
1,180 $14,000
Q1 2021

May 17, 2021

BUY
$17.13 - $27.25 $10,517 - $16,731
614 New
614 $14,000

Others Institutions Holding TERN

About Terns Pharmaceuticals, Inc.


  • Ticker TERN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 37,613,800
  • Market Cap $218M
  • Description
  • Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical t...
More about TERN
Track This Portfolio

Track Tower Research Capital LLC (Trc) Portfolio

Follow Tower Research Capital LLC (Trc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.